Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Scorpius Holdings ( (SCPX) ) has issued an announcement.
On December 10, 2025, Scorpius Holdings, Inc. had substantially all of its non-cash assets tied to its CDMO and R&D operations foreclosed upon in an Article 9 Uniform Commercial Code sale conducted by a collateral agent on behalf of secured noteholders, resulting in the disposition of a significant portion of the company’s assets and the termination of all CDMO employees, most of whom subsequently joined Velocity Bioworks, a subsidiary of Tivic Health Systems, the buyer of the assets. The foreclosure generated net proceeds of $15.2 million that were applied to partially settle secured debt that stood at $30.2 million immediately before closing, and Scorpius has now recast the divested business as discontinued operations and prepared unaudited pro forma consolidated financial information to show the impact of the disposal on its balance sheet and results of operations for 2023, 2024 and the first half of 2025.
The most recent analyst rating on (SCPX) stock is a Hold with a $0.01 price target. To see the full list of analyst forecasts on Scorpius Holdings stock, see the SCPX Stock Forecast page.
Spark’s Take on SCPX Stock
According to Spark, TipRanks’ AI Analyst, SCPX is a Underperform.
The score is driven primarily by weak financial performance (declining revenue, ongoing losses, negative cash flow, and high leverage). Technicals also point to a bearish trend with negative MACD and the stock trading below key moving averages. Recent negative corporate events around defaults, potential asset sale, and additional short-term debt further pressure the outlook, while valuation is limited by ongoing losses and no dividend support.
To see Spark’s full report on SCPX stock, click here.
More about Scorpius Holdings
Scorpius Holdings, Inc. operated a contract development and manufacturing organization (CDMO) alongside research and development activities, with its key non-cash assets and related subsidiaries focused on providing development and manufacturing services to biopharmaceutical customers.
Average Trading Volume: 3,040
Technical Sentiment Signal: Sell
Current Market Cap: $122.3K
Find detailed analytics on SCPX stock on TipRanks’ Stock Analysis page.